TREATMENT OF RELAPSES AND RESISTANT FORMS OF HODGKIN'S LYMPHOMA


Citar

Texto integral

Acesso aberto Acesso aberto
Acesso é fechado Acesso está concedido
Acesso é fechado Acesso é pago ou somente para assinantes

Resumo

High-dose chemotherapy with autologous hematopoietic stem cell transplantation (HDCT с autoHSCT) is a modern standard for the treatment of primary refractory forms and the first relapses of Hodgkin’s lymphoma (HL). HDCT with autoHSCT is effective for 50-60% of patients with the first late chemosensitive relapse of HL. Chemoresistance is defined as a predictive factor for an unfavorable prognosis. Allogeneic hematopoietic stem cell transplantations (alloHSCT) can be performed in case of recurrence of HL after HDCT with autoHSCT with preserved chemosensitivity, and are preferable for young patients in prospective clinical trials. Among the monoclonal antibodies studied, the greatest therapeutic activity was detected for brentuximab vedotin. Brentuximab vedotin is registered for the treatment of patients with classic HL after failure (progression or early relapse) of HDCT with autoHSCT or patients who are not candidates for high-dose CT., if two or more HT lines fail, for consolidation after HDCT with autoHSCT in HL patients with a high risk for recurrence or progression. The high activity of PD-1/PD-L1 checkpoint inhibitors, activating antitumor immunity (nivolumab, pembolizumab) was noted for patients with recurrence of HL. Promising areas of therapy for HL are associated with further study of new targets of tumor cells and their signaling pathways.

Texto integral

Acesso é fechado

Sobre autores

L. Filatova

N.N. Petrov National Medical Research Center of Oncology; North-Western State Medical University n.a. I.I. Mechnikov

Email: Larisa_Filatova@list.ru
MD, Leading Researcher at the Scientific Department of Innovative Methods of Therapeutic Oncology and Rehabilitation; Associate Professor at the Department of Oncology Saint-Petersburg, Russia

M. Motalkina

N.N. Petrov National Medical Research Center of Oncology

Saint-Petersburg, Russia

E. Kharchenko

N.N. Petrov National Medical Research Center of Oncology

Saint-Petersburg, Russia

I. Ishmatova

N.N. Petrov National Medical Research Center of Oncology

Saint-Petersburg, Russia

I. Zyuzgin

N.N. Petrov National Medical Research Center of Oncology

Saint-Petersburg, Russia

P. Shilo

N.N. Petrov National Medical Research Center of Oncology

Saint-Petersburg, Russia

Yu. Oleinik

N.N. Petrov National Medical Research Center of Oncology

Saint-Petersburg, Russia

Yu. Chudinovskikh

N.N. Petrov National Medical Research Center of Oncology; North-Western State Medical University n.a. I.I. Mechnikov

Saint-Petersburg, Russia

T. Semiglazova

N.N. Petrov National Medical Research Center of Oncology

Saint-Petersburg, Russia

Bibliografia

  1. Santoro A., Bredenfeld H., Devizzi L., et al. Gemcitabine in the treatment of refractory Hodgkin's disease: results of a multicenter phase II study. J. Clin. Oncol. 2000;18:2615-19.
  2. Venkatesh H., Di Bella N., Flynn TР., et al. Results of a phase II multicenter trial of singleagent gemcitabine in patients with relapsed or chemotherapy-refractory Hodgkin's lymphoma. Clin. Lymphoma. 2004; 5:110-15.
  3. Oki Y., Younes A. Current role of gemcitabine in the treatment of Hodgkin lymphoma. Leuk. Lymphoma. 2008;49(5):883-89.
  4. Corazzelli G., Frigeri F., Marcacci G., et al. Rituximab plus gemcitabine, ifosfamide, oxaliplatin (R-GIFOX) as salvage therapy for recurrent Hodgkin lymphoma. J. Clin. Oncol. 2009;27:15s.
  5. Moskowitz A.J. Novel agents in Hodgkin lymphoma. Curr Oncol. Rep. 2012;14:419-23.
  6. Josting A., Franklin J., May M., et al. New prognostic score based on treatment outcome of patients with relapsed Hodgkin's lymphoma registered in the database of the German lymphoma study group. J. Clin. Oncol. 2002;20:221-30.
  7. Moskowitz C.H., Nimer S.D., Zelenetz A.D., et al. A 2-step comprehensive high-dose chemoradiotherapy second-line program for relapsed and refractory Hodgkin disease: analysis by intent to treat and development of a prognostic model. Blood. 2001;97:616-23.
  8. Kuruvilla J., Nagy T., Pintilie M., et al. Similar response rates and superior early progression-free survival with gemcitabine, dexamethasone, and cisplatin salvage therapy compared with carmustine, etoposide, cytarabine, and melphalan salvage therapy prior to autologous stem cell transplantation for recurrent or refractory Hodgkin lymphoma. Cancer. 2006;106:353-60.
  9. Bartlett N.L., Niedzwiecki D., Johnson L., et al. Gemcitabine, vinorelbine, and pegylated liposomal doxorubicin (GVD), a salvage regimen in relapsed Hodgkin's lymphoma: CALGB 59804. Ann. Oncol. 2007;18:1071-79.
  10. Santoro A., Magagnoli M., Spina M., et al. Ifosfamide, gemcitabine, and vinorelbine: a new induction regimen for refractory and relapsed Hodgkin's lymphoma. Haematologica. 2007;92:35-41.
  11. LaCasce A.S., Bociek G., Sawas A., et al. Brentuximab Vedotin Plus Bendamustine: A Highly Active Salvage Treatment Regimen for Patients with Relapsed or Refractory Hodgkin Lymphoma. Blood. 2015;126 (23):3982.
  12. Gallamini A., Patti C., Viviani S., et al. Early chemotherapy intensification with BEACOPP in advanced-stage Hodgkin lymphoma patients with a interim-PET positive after two ABVD courses. Br. J. Haematol. 2011;152:551-60.
  13. Linch D.C., Winfield D., Goldstone A.H., et al. Dose intensification with autologous bone-marrow transplantation in relapsed and resistant Hodgkin's disease. Lancet. 1993;341:1051-54.
  14. Schmitz N., Haverkamp H., Josting A., et al. Long term follow up in relapsed Hodgkin's disease (HD): Updated results of the HD-R1 study comparing conventional chemotherapy (cCT) to high-dose chemotherapy (HDCT) with autologous haemopoetic stem cell transplantation (ASCT) of the German Hodgkin Study Group (GHSG) and the Working Party Lymphoma of the European Group for Blood and Marrow Transplantation (EBMT). J. Clin. Oncol. 2005;23:562s. (Abstr. 6508).
  15. Josting A., Muller H., Borchmann P., et al. Dose intensity of chemotherapy in patients with relapsed Hodgkin's lymphoma. J. Clin. Oncol. 2010; 28:5074-80.
  16. Ferme C., Mounier N., Divine M., et al. Intensive salvage therapy with high-dose chemotherapy for patients with advanced Hodgkin' s disease in relapse or failure after initial chemotherapy: results of the Group d'Etudes des Lymphomes de l'Adulte H89 Trial. J. Clin. Oncol. 2002;20:467-75.
  17. Sirohi B., Cunningham D., Powles R., et al. Long-term outcome of autologous stem-cell transplantation in relapsed or refractory Hodgkin's lymphoma. Ann. Oncol. 2008;19:1312-19.
  18. Castagna L., Magagnoli M., Balzarotti M., et al. Tandem high-dose chemotherapy and autologous stem cell transplantation in refractory/relapsed Hodgkin's lymphoma: A monocenter prospective study. Am. J. Hematol. 2007;82:122-27.
  19. Constans M., Sureda A., Terol M.J., et al. Autologous stem cell transplantation for primary refractory Hodgkin's disease: results and clinical variables affecting outcome. Ann. Oncol. 2003;14:745-51.
  20. Fung H.C., Stiff P., Schriber J., et al. Tandem autologous stem cell transplantation for patients with primary refractory or poor risk recurrent Hodgkin lymphoma. Biol. Blood Marrow Transplant. 2007;13:594-600.
  21. Morschhauser F., Brice P., Ferme C., et al. Risk-adapted salvage treatment with single or tandem autologous stem-cell transplantation for first relapse/ refractory Hodgkin's lymphoma: Results of the prospective multicenter H96 trial by the GELA/SFGM study group. J. Clin. Oncol. 2008;26:5980-87.
  22. Kuruvilla J., Keating A., Crump M. How I treat relapsed and refractory Hodgkin lymphoma. Blood. 2011;117:4208-17.
  23. Anderson J.E., Litzow M.R., Appelbaum F.R., et al. Allogeneic, syngeneic, and autologous marrow transplantation for Hodgkin's disease: The 21-year Seattle experience. J. Clin. Oncol. 1993;11:2342-50.
  24. Milpied N., Fielding A.K., Pearce R.M., et al. Allogeneic bone marrow transplant is notbetter than autologous transplant for patients with relapsed Hodgkin's disease. European Group for Blood and Bone Marrow Transplantation. J. Clin. Oncol. 1996;14:1291-96.
  25. Robinson S.P., Sureda A., Canals C., et al. Reduced intensity conditioning allogeneic stem cell transplantation for Hodgkin's lymphoma indentification of prognostic factors predicting outcome. Haematologica. 2009;94:230-38.
  26. Alvarez I., Sureda A., Caballero M.D., et al. Nonmyeloablative stem cell transplantation is an effective therapy for refractory or relapsed Hodgkin lymphoma: results of a Spanish prospective cooperative protocol. Biol. Blood Marrow Transplant. 2006;12:172-83.
  27. Carella A.M., Cavaliere M., Lerma E., et al. Autografting followed by nonmyeloablative immunosuppressive chemotherapy and allogenec peripheral blood hemopoietic stem cell transplantation as treatment of resistant Hodgkin's disease and non-Hodgkin's lymphoma. J. Clin. Oncol. 2000;18:3918-24.
  28. Farina L., Castagna L., Farina L., et al. Allogeneic transplantation improves the overall and progression-free survival of Hodgkin lymphoma patients relapsing after autologous transplantation: a retrospective study based on the time of HLA typing and donor availability. Blood. 2010;115:3671-77.
  29. James P. Salvage therapy in Hodgkin's lymphoma. Oncologist. 2009;14:425-32.
  30. Moskowitz C.H., Nimer S.D., Zelenetz A.D., et al. A 2-step comprehensive high-dose chemo-radiotherapy second-line program for relapsed and refractory Hodgkin disease: analysis by intent to treat and development of a prognostic model. Blood. 2001;97:616-23.
  31. Evens A.M., Altman J.K., Mittal B.B., et al. Phase I/II trial of total lymphoid irradiation and highdose chemotherapy with autologous stem-cell transplantation for relapsed and refractory Hodgkin's lymphoma. Ann. Oncol. 2007;18:679-88.
  32. Brice P. Managing relapsed and refractory Hodgkin lymphoma. Br. J. Haematol. 2008;141:3-13.
  33. Josting A., Muller H., Borchmann P., et al. Dose intensity of chemotherapy in patients with relapsed Hodgkin's lymphoma. J. Clin. Oncol. 2010; 28:5074-80.
  34. Campbell B., Winh A., Milner A., et al. Long-term follow-up of salvage radiotherapy in Hodgkin's lymphoma after chemotherapy failure. Int. J. Radiat. Oncol. Biol. Phys. 2005;63:1538-45.
  35. Tsang R.W., Goda J.S., Massey C., et al. What can be expected from salvage radiation therapy when an autologous stem cell transplant fails to control Hodgkin lymphoma? Haematologica. 2010;95:S27. (Abstr. P092).
  36. Freedman A.S., Kuruvilla J., Assouline S., et al. Clinical activity of lucatumumab (HCD122) in patients (pts) with relapsed/refractory Hodgkin or non-Hodgkin lymphoma treated in a phase Ia/II clinical trial (NCT00670592). Blood. 2010;116. Abstr. 284.
  37. Smith S.M., Schooder H., Johnson J.L., et al. The anti- CD80 primatized monoclonal antibody, galiximab, is well-tolerated but has limited activity in relapsed Hodgkin lymphoma: Cancer and leukemia Group B 50602 (Alliance). Leuk. Lymphoma. 2013; 54:1405-10.
  38. Gopal A.K, Chen R., Smith S.E., et al. Durable remissions in a pivotal phase 2 study of brentuximab vedotin in relapsed or refractory Hodgkin lymphoma. Blood. 2015;125:1236-43.
  39. Perrot A., Monjanel H., Bouabdallah R., et al. Lymphoma Study Association (LYSA). Impact of post-brentuximab vedotin consolidation on relapsed/ refractory CD30+ Hodgkin lymphomas: a large retrospective study on 240 patients enrolled in the French Named-Patient Program. Haematologica. 2016;101:466-73.
  40. Moskowitz C.H., Nadamanee A., Masszi T., et al. Brentuximab vedotin as consolidation therapy after autologous stem-cell transplantation in patients with Hodgkin's lymphoma at risk of relapse or progression (AETHERA): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet. 2015;385: 1853-62.
  41. Batlevi C.L., Younes A. Novel therapy for Hodgkin lymphoma. Hematology Am. Soc. Hematol. Educ. Program. 2013;2013:394-99.
  42. Younes А., Сonnors J.M., Park S.I., et al. Brentuximab vedotin combined with ABVD or AVD for patients with newly diagnosed Hodgkin's lymphoma: a phase 1, open-label, dose-escalation study. Lancet Oncology. 2013;14:1348-56.
  43. Ansell S.M., Lesokhin A.M., Borrello I., et al. PD-1 blockade with nivolumab in relapsed or refractory Hodgkin's lymphoma. N. Engl. J. Med. 2015;372:311-19.
  44. Chen R.W., Zinzani P.L., Fanale M.A., et al. Pembrolizumab for relapsed/refractory classical Hodgkin lymphoma (R/R cHL): phase 2 KEYNOTE-087 study. J. Clin. Oncol. 2016;34. Abstr. 7555.
  45. Moskowitz C.H., Zinzani P., Fanale M., et al. Pembrolizumab in Relapsed/Refractory Classical Hodgkin Lymphoma: Primary End Point Analysis of the Phase 2 Keynote-087 Study. Blood. 2016; 128:1107.
  46. Oki Y., Pro B., Fayad L.E., et al. Phase 2 study of gemcitabine in combination with rituximab in patients with recurrent or refractory Hodgkin lymphoma. Cancer. 2008;112:831-36.
  47. Younes A., Oki Y., McLaughlin P., et al. Phase 2 study of rituximab plus ABVD in patients with newly diagnosed classical Hodgkin lymphoma. Blood. 2012;119:4123-28.
  48. Younes A., Oki Y., Bociek R.G., et al. Mocetinostat for relapsed classical Hodgkin's lymphoma: an open-label, single-arm, phase 2 trial. Lancet Oncol. 2011;112:1222-28.
  49. Younes A., Sureda A., Ben-Yehuda D., et al. Panobinostat in patients with relapsed/refractory Hodgkin's lymphoma after autologous stem-cell transplantation: results of a phase II study. J. Clin. Oncol. 2012;30:2197-203.
  50. Oki Y., Fanale M.A., Westin J.R., et al. A phase I study of panobinostat in combination with ICE (Ifosfamide, Carboplatin and Etoposide) In patients with relapsed or refractory classical Hodgkin lymphoma (cHL). Blood. 2013;122:252.
  51. Fehniger T.A., Larson S., Trinkaus K., et al. A phase II multicenter study of lenalidomide in patients with relapsed or refractory classical Hodgkin lymphoma. Blood. 2011;118:5119-25.
  52. Kuruvilla J., Song K., Mollee Р., et al. A phase ii study of thalidomide and vinblastine for palliative patients with Hodgkin's lymphoma. Hematology. 2006; 11:25-9.
  53. Johnston PB., Inwards D.J., Colgan J.Р., et al. A Phase II trial of the oral Mtor inhibitor everolimus in relapsed Hodgkin lymphoma. Am. J. Hematol. 2010; 85:320-24.
  54. Lemoine M., Derenzini E., Buglio D., et al. The pan-deacetylase inhibitor panobinostat induces cell death and synergizes with everolimus in Hodgkin lymphoma cell lines. Blood. 2012;119:4017-25.
  55. Oki Y., Buglio D., Fanale M., et al. Phase I study of panobinostat plus everolimus in patients with relapsed or refractory lymphoma. Clin. Cancer Res. 2013;19:6882-90.
  56. Janku F., Oki Y., Falchook G.S., et al. Activity of the mTOR inhibitor sirolimus and HDAC inhibitor vorinostat in heavily pretreated refractory Hodgkin lymphoma patients. ASCO Meeting Abstracts. 2014;32:8508.

Arquivos suplementares

Arquivos suplementares
Ação
1. JATS XML
Baixar

Declaração de direitos autorais © Bionika Media, 2018

Este site utiliza cookies

Ao continuar usando nosso site, você concorda com o procedimento de cookies que mantêm o site funcionando normalmente.

Informação sobre cookies